BPR1M97;Benzamide, 3,4-dichloro-N-[(1,2,3,4-tetrahydro-2-methyl-1-isoquinolinyl)methyl]-;3,4-Dichloro-N-[(1,2,3,4-tetrahydro-2-methyl-1-isoquinolinyl)methyl]benzamide;BPR1M97, 10 mM in DMSO
BPR1M97 is a dual-acting agonist of the mu opioid receptor (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor, with Ki values of 1.8 nM and 4.2 nM, respectively; it exhibits high efficacy, blood-brain barrier permeability, and potent antinociceptive effects; it demonstrates antinociception in a murine model of cancer pain following a single subcutaneous administration (1.8 mg/kg).